MAPK3 and arthritic joint disease: Importantly, Syk and P38 (reduced development of STIA in Syk-deficient or P38 inhibitor-treated mice), as well as ERK1/2 (Fc-receptor stimulation leads to ERK1/2 activation), have been implicated in the context of arthritis [56,57,58,59].